As the American Society of Clinical Oncology (ASCO) meeting entered day two, coffee-sipping attendees perked to a first-in-the-morning discussion of the phase III data with Pharmacyclics Inc.’s ibrutinib (branded Imbruvica) in relapsed chronic lymphocytic leukemia (CLL), the first time an oral drug has yielded survival improvement over standard therapy. CLL is usually treated with chemo-immunotherapy, […]
written on 19.06.2014